Maze Therapeutics (NASDAQ:MAZE) SVP Amy Bachrodt Sells 5,000 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 5,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $39.15, for a total transaction of $195,750.00. Following the completion of the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $507,579.75. The trade was a 27.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Amy Bachrodt also recently made the following trade(s):

• On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.58, for a total transaction of $405,800.00.
• On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.08, for a total transaction of $200,400.00.

Maze Therapeutics Price Performance

Maze Therapeutics stock opened at $38.37 on Wednesday. The stock has a market cap of $1.85 billion and a price-to-earnings ratio of -1.84. The firm has a 50-day moving average of $37.28 and a two-hundred day moving average of $25.45. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $43.29.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MAZE. HC Wainwright upped their target price on Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. Raymond James Financial assumed coverage on shares of Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price objective for the company. Wedbush raised their target price on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and an average price target of $43.38.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after buying an additional 1,725 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Maze Therapeutics in the 3rd quarter valued at about $52,000. CWM LLC bought a new stake in shares of Maze Therapeutics in the 2nd quarter valued at about $28,000. Finally, Legal & General Group Plc grew its position in shares of Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after buying an additional 3,371 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.